CA
NZ
UK
AU
IND
US
That matters because dosing convenience has become almost as important as raw efficacy in this category. GLP-1 and dual-agonist obesity drugs already work — the market has largely moved on to asking which ones patients will actually stick with. A treatment that lets people …
The therapy itself represents one of the more scientifically ambitious applications of mRNA technology outside of infectious disease. Intismeran autogene is built as a personalized neoantigen therapy, meaning each patient's vaccine is manufactured based on the specific genetic mutations found in their own tumor. …
For context, antibody-antigen inference refers to computational modeling of how antibodies — the immune system's targeting molecules — interact with antigens, the molecular structures they bind to. This kind of modeling sits at the center of modern computational drug discovery, particularly forBiologicsand antibody-based therapeutics, …
The logic behind the deal isDiversificationwithin a single indication. Lexeo's existing flagship program, LX2006, is a gene therapy, a one-time treatment approach that works by delivering a functional copy of a gene directly into cells. The MantleAssetstake entirely different mechanisms: an oral drug that …
FDA advisory committee briefing documents are prepared by the agency's own staff in advance of a public meeting where outside experts vote on and discuss a product's benefit-risk profile. While these documents don't represent a final regulatory decision, they often set the tone for …
Viking Therapeutics (NASDAQ:VKTX) shares rose in pre-market trading Tuesday as investors positioned ahead of key maintenance-dosing data for its lead obesity candidate, VK2735, expected this quarter. Viking Therapeutics is a San Diego-based, clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class therapies for …
Quest Diagnostics (NYSE:DGX) shares slid sharply in pre-market trading Tuesday, pulling back from Monday's close near $246, as peer LabCorp (NYSE:LH) also fell on news that new Medicare lab payment cuts from the Centers for Medicare & Medicaid Services are weighing on the diagnostics …
Omada Health (NASDAQ:OMDA) shares are extending gains in pre-market trading Tuesday after the digital chronic-disease management company was added to the S&P Health Care Services Select IndustryindexMonday, a technical inclusion that can drive incremental passive-fund buying and raise visibility among institutional investors. Omada Health …
AnaptysBio (NASDAQ:ANAB) shares rose in pre-market trading Tuesday as investors responded positively to a strong second-quarter fiscal 2026 earnings report released after Monday's close. The report reflected a streamlined, royalty-focusedBusinessfollowing the April 2026 spin-off of First Tracks Biotherapeutics. AnaptysBio manages the financial collaborations for …
Apnimed (NASDAQ:APMD) shares are sliding today even as most other clinical-stage and specialty pharmaceutical names trade higher, a divergence that points to company-specific selling rather than a sector-wide shift in sentiment. Apnimed is a clinical-stage pharmaceutical company developing an oral therapy for obstructive sleep …
Please wait processing your request...